Дисертації з теми "Meningioma tumors"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-33 дисертацій для дослідження на тему "Meningioma tumors".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте дисертації для різних дисциплін та оформлюйте правильно вашу бібліографію.
Qureshi, Hammad A. "Meningioma classification using an adaptive discriminant wavelet packet transform." Thesis, University of Warwick, 2009. http://wrap.warwick.ac.uk/2790/.
Повний текст джерелаWibom, Carl. "Multivariate analyses of proteomic and metabolomic patterns in brain tumors." Doctoral thesis, Umeå universitet, Onkologi, 2009. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-25670.
Повний текст джерелаLombardi, Ismael Augusto Silva [UNESP]. "Metilação e expressão do gene BRCA1 em meningiomas." Universidade Estadual Paulista (UNESP), 2013. http://hdl.handle.net/11449/88064.
Повний текст джерелаMeningiomas são os tumores intracranianos primários mais comuns e correlacionam-‐se com câncer de mama, compatilhando características como incidência maior no sexo feminino, receptores para hormônios sexuais e crescimento a exposição a hormônios sexuais. O gene BRCA1 é amplamente estudado no câncer de mama hereditário e esporádico, entretanto, são poucos os trabalhos que correlacionam BRCA1 e meningiomas. O BRCA1 é gene de supressão tumoral, interagindo com outros oncogenes, atuando no reparo do DNA durante a divisão celular e modulando negativamente receptores de estrógeno e progesterona. Avaliar o padrão de metilação de e expressão de BRCA1 em meningiomas e tecidos controles, e a expressão de receptores de estrógeno e progesterona em meningiomas e controles, correlacionando estes dados com dados epidemiológicos da casuística. Casuística e métodos: pacientes com diagnóstico de meningiomas tiveram amostras tumorais colhidas durante cirurgias de rotina pela disciplina de Neurocirurgia da Faculdade de Medicina de Botucatu (FMB) e do Hospital Mário Gatti, em Campinas. Previamente, o projeto foi aprovado pelo Comitê de Ética em Pesquisa e cada paciente concordou em participar ao assinar o Termo de Consentimento Livre e Esclarecido. Amostras controle de aracnóide foram colhidas de cadáveres no serviço de necropsia da disciplina de Patologia da FMB. As amostras tumorais foram avaliadas para metilação de BRCA1 por PCR específica para metilação e os resultados avaliados por eletroforese. A expressão foi avaliada por PCR em tempo real os resultados dados em relação a amostras comtroles. A expressão de receptores de estrógeno (RE) e progesterona (RP) foram analisadas por imuno-histoquímica, conforme rotina da disciplina de Patologia da FMB. Foram avaliados 50 meningiomas entre...
Meningiomas are the most common primary intracranial tumors and correlate with breast cancer, shearing features like higher incidence in female, sexual hormone receptors and growth to exposure to sexual hormones. The gene is widely studied in hereditary and sporadic breast cancer, however, there are few studies that correlate BRCA1 and meningiomas. The BRCA1 is a tumor suppressor gene and interacts with other oncogenes by DNA repairing during cell division and also negative modulating estrogen and progesterone receptors. To assess the pattern of methylation and expression of BRCA1 in meningiomas and control tissues, and the expression of estrogen and progesterone receptors in meningiomas and control tissues, and to correlate these data with patients epidemiological data. Patients diagnosed with meningioma had collected tumors samples during routine surgeries by the discipline of Neurosurgery in Faculty of Medicine of Botucatu (FMB) and Mario Gatti Hospital in Campinas. Previously, the project was approved by the Research Ethics Committee and each patient agreed to participate by signing the Instrument of Consent. Control arachnoid samples were collected from cadavers during routine of necropsy of Pathology departament in FMB. The tumor samples were analyzed for methylation of BRCA1 by methylation specific PCR and the results were evaluated by electrophoresis. The expression was assessed by real-‐time PCR results given in relation to samples comtroles. The expression of estrogen receptors (ER) and progesterone (PR) were analyzed by immunohistochemistry, as routine in Pathology departament. There were 50 meningiomas between January 2009 to September 2012, 22 male and 28 female. The methylation of BRCA1 in meningiomas was statistically significant compared to control tissues... (Complete abstract click electronic access below)
Lombardi, Ismael Augusto Silva. "Metilação e expressão do gene BRCA1 em meningiomas /." Botucatu : [s.n.], 2013. http://hdl.handle.net/11449/88064.
Повний текст джерелаCoorientador: Maria Inês de Moura Campos Pardini
Coorientador: Marco Antonio Zanini
Banca: Carlos Gilberto Carlotti Junior
Banca: Eny Maria Goloni-Bertollo
Resumo: Meningiomas são os tumores intracranianos primários mais comuns e correlacionam-‐se com câncer de mama, compatilhando características como incidência maior no sexo feminino, receptores para hormônios sexuais e crescimento a exposição a hormônios sexuais. O gene BRCA1 é amplamente estudado no câncer de mama hereditário e esporádico, entretanto, são poucos os trabalhos que correlacionam BRCA1 e meningiomas. O BRCA1 é gene de supressão tumoral, interagindo com outros oncogenes, atuando no reparo do DNA durante a divisão celular e modulando negativamente receptores de estrógeno e progesterona. Avaliar o padrão de metilação de e expressão de BRCA1 em meningiomas e tecidos controles, e a expressão de receptores de estrógeno e progesterona em meningiomas e controles, correlacionando estes dados com dados epidemiológicos da casuística. Casuística e métodos: pacientes com diagnóstico de meningiomas tiveram amostras tumorais colhidas durante cirurgias de rotina pela disciplina de Neurocirurgia da Faculdade de Medicina de Botucatu (FMB) e do Hospital Mário Gatti, em Campinas. Previamente, o projeto foi aprovado pelo Comitê de Ética em Pesquisa e cada paciente concordou em participar ao assinar o Termo de Consentimento Livre e Esclarecido. Amostras controle de aracnóide foram colhidas de cadáveres no serviço de necropsia da disciplina de Patologia da FMB. As amostras tumorais foram avaliadas para metilação de BRCA1 por PCR específica para metilação e os resultados avaliados por eletroforese. A expressão foi avaliada por PCR em tempo real os resultados dados em relação a amostras comtroles. A expressão de receptores de estrógeno (RE) e progesterona (RP) foram analisadas por imuno-histoquímica, conforme rotina da disciplina de Patologia da FMB. Foram avaliados 50 meningiomas entre... (Resumo completo, clicar acesso eletrônico abaixo)
Abstract: Meningiomas are the most common primary intracranial tumors and correlate with breast cancer, shearing features like higher incidence in female, sexual hormone receptors and growth to exposure to sexual hormones. The gene is widely studied in hereditary and sporadic breast cancer, however, there are few studies that correlate BRCA1 and meningiomas. The BRCA1 is a tumor suppressor gene and interacts with other oncogenes by DNA repairing during cell division and also negative modulating estrogen and progesterone receptors. To assess the pattern of methylation and expression of BRCA1 in meningiomas and control tissues, and the expression of estrogen and progesterone receptors in meningiomas and control tissues, and to correlate these data with patients epidemiological data. Patients diagnosed with meningioma had collected tumors samples during routine surgeries by the discipline of Neurosurgery in Faculty of Medicine of Botucatu (FMB) and Mario Gatti Hospital in Campinas. Previously, the project was approved by the Research Ethics Committee and each patient agreed to participate by signing the Instrument of Consent. Control arachnoid samples were collected from cadavers during routine of necropsy of Pathology departament in FMB. The tumor samples were analyzed for methylation of BRCA1 by methylation specific PCR and the results were evaluated by electrophoresis. The expression was assessed by real-‐time PCR results given in relation to samples comtroles. The expression of estrogen receptors (ER) and progesterone (PR) were analyzed by immunohistochemistry, as routine in Pathology departament. There were 50 meningiomas between January 2009 to September 2012, 22 male and 28 female. The methylation of BRCA1 in meningiomas was statistically significant compared to control tissues... (Complete abstract click electronic access below)
Mestre
Mörén, Lina. "Metabolomics and proteomics studies of brain tumors : a chemometric bioinformatics approach." Doctoral thesis, Umeå universitet, Kemiska institutionen, 2015. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-111309.
Повний текст джерелаPrager, Briana C. "THE MENINGIOMA ENHANCER LANDSCAPE DELINEATES PROGNOSTIC SUBGROUPS AND DRIVES DRUGGABLE DEPENDENCIES." Case Western Reserve University School of Graduate Studies / OhioLINK, 2020. http://rave.ohiolink.edu/etdc/view?acc_num=case1595620620551252.
Повний текст джерелаGhasimi, Soma. "Genotype-phenotype studies in brain tumors." Doctoral thesis, Umeå universitet, Onkologi, 2013. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-83185.
Повний текст джерелаCancer research foundation in northern Sweden and Lions cancer research foundation at Umeå university
Hansson, Caisa Marie. "Analysis of Genetic Alterations in Patients Affected with Neurofibromatosis Type 2 and its Associated Tumors." Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2006. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-6511.
Повний текст джерелаBuckley, Patrick. "Development and Application of Microarray-Based Comparative Genomic Hybridization : Analysis of Neurofibromatosis Type-2, Schwannomatosis and Related Tumors." Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2005. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4786.
Повний текст джерелаAlmeida, Luciana Oliveira de. "Análise epigenética e de polimorfismos em tumores extra-axiais do sistema nervoso." Universidade de São Paulo, 2009. http://www.teses.usp.br/teses/disponiveis/17/17135/tde-02032010-121437/.
Повний текст джерелаThe extra-axial brain tumors have extra-brain localization and in most of the time they are benign, meningiomas, schwannomas and metastasis are included in this group. The appearance of a tumor occurs because of the accumulation of genetic and epigenetic alterations in the cells. In order to understand the molecular mechanism of the tumor progression and the metastasis formation it is important to identify the genes that accumulate the alterations. Thereby, the objective of this study was to analyze the methylation profile of the genes TP16, TP53, DAL-1, GSTP-1, MEN-1, NDRG2 and the DNA methyltransferases 3A, 3B and 3L and their association with the extra-axial brain tumors. Another purpose was to determine, in a case-control study, the roles of the TP53 Pro47Ser and Arg72Pro, EGF + 61, GSTP-1 Ile105Val and WRN Cys1367Arg SNPs in the development and prognosis of these tumors. We used the MSP to screen the hypermethylation profile and we observed no association between the DNMTs activity and the hypermethylation of the tumors. We also did not find association between the methylation of the DNMTs de novo and alterations in the methylation profile of the genes TP16, TP53, DAL-1, GSTP-1, MEN-1 and NDRG2. We observed that TP53 hypermethylation was associated with the high grade tumors, a poor response to the treatments and, consequently, the high number of obits. The TP16 methylation was involved with the shwannomas formation and the NDRG2 gene was involved in the meningiomas progression. For the polymorphism analysis, we used the PCR-RFLP technique and we observed differences in the genotype distributions between cases and controls of TP53 Pro47Ser and Arg72Pro, EGF + 61 and GSTP-1 Ile105Val SNPs, where the variants Ser47, Pro72, EGF G61 and Val105 were more frequent in patients than in controls. Thus, these variants can be important factors of susceptibility to the tumor development.
Rosa, Marcella Suelma de Torrecillas. "Expressão tecidual e sérica de microRNAs associados a receptores de estrógeno e progesterona em meningiomas grau I, II e III." Universidade de São Paulo, 2018. http://www.teses.usp.br/teses/disponiveis/17/17137/tde-09112018-110503/.
Повний текст джерелаMeningiomas are the most common primary Central Nervous System (CNS) tumors, accounting for 35.5% of the cases, considering all age groups. Despite the progress made in recent decades, the tumorigenesis of meningiomas still remains a challenge. There is a consensus of the need for molecular tools to assist both diagnosis and prognosis of meningiomas. In this context, some studies demonstrate the importance of the role of estrogen and progesterone receptors, as well as the understanding of alterations in microRNA (miRNAs) expression levels in the tumorigenesis of meningiomas. Some studies have shown that the serum expression profile of the miRNAs correlates with the classification and clinical evolution, being of great interest the use of this material because it is a non-invasive procedure, i.e., as biomarkers. Objectives: To evaluate the tissue and serum expression profile of microRNAs associated with the estrogen and progesterone receptor pathways in meningiomas grade I, II and III. Patients and methods: tissue and blood samples from 40 patients with grade I, II and III meningiomas were used. For analysis of miRNA expression miR-34a, miR-143, miR-145 and miR-335 was used the real-time PCR technique. Results: miRNAs: miR-34a and miR-145 presented a significant statistical difference in the tumor tissue samples between the groups with lower expression in the samples of grade II meningiomas when compared to samples I and III. We did not observe statistically significant statistical difference in miRNA expression in blood samples. Conclusion: the selected miRNAs showed no correlation with tumor progression in meningiomas.
Carneiro, Vinicius Marques. "Perfil de expressão tecidual e plasmática dos microRNAs miR-130a, miR-181c e miR-181d em meningiomas grau I, II e III." Universidade de São Paulo, 2015. http://www.teses.usp.br/teses/disponiveis/17/17137/tde-01022016-155451/.
Повний текст джерелаIntroduction: Meningiomas are intracranial tumors of slow growth that originate from meningothelial arachnoid cells and represents the most common intracranial tumors, accounting for 13-26% of this total, beeing one of the first solid tumors to have identified genetic alterations There are technological advances available to a better understanding of the molecular pathways correlated with tumorigenesis and tumor progression of meningiomas. The role of microRNAs in this process is very importante. MicroRNAs are non-coding RNAs (ncRNAs) consisting of 19 to 25 nucleotides, with function of mRNA silencing post-transcriptional level. The aim of our study was to evaluate the tissue expression and plasma of miRNAs miR-181d, miR-181c and miR-130a. Patients and methods: The miRNAs miR-181d, miR-181c and miR-130a were selected from a previous study of our group by analysis technique on large scale called microarrays, which were compared meningiomas grade I with arachnoid controls samples. In this study, we evaluated expression of these miRNAs in tumor tissue and plasma meningiomas grade I, II and III. Results: The miR-181d was presented upregulated in the all groups in both tumor tissue and in plasma. The level of expression was increased according to the progression of tumor grade. The miR-181c and miR-130a showed no statistical difference in the groups studied in both tumor tissue and plasma. Conclusions: The miR-181d has potential as a biomarker for meningiomas and is associated with tumor progression.
Bassiri, Kayleigh. "Identifying common therapeutic targets in Merlin-deficient brain tumours." Thesis, University of Plymouth, 2016. http://hdl.handle.net/10026.1/8068.
Повний текст джерелаValer, Gonzales Dante. "Incidencia, localización y recidiva de los meningiomas cerebrales." Bachelor's thesis, Universidad Nacional Mayor de San Marcos, 2014. https://hdl.handle.net/20.500.12672/13063.
Повний текст джерелаTrabajo académico
SUGIURA, MITSUO, and HIROJI KUCHIWAKI. "Septic Shock with Hyperglycemia Induced by Hypothalamic Dysfunction after Removal of Large Parasagittal Meningioma." Nagoya University School of Medicine, 1988. http://hdl.handle.net/2237/17501.
Повний текст джерелаWayhs, Samia Yasin. "Influência da abordagem cirúrgica na ressecção dos meningiomas petroclivais." reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2015. http://hdl.handle.net/10183/148212.
Повний текст джерелаPetroclival meningiomas are challenging skull base tumors for surgical resection because of its deep location and their relationship to vital neurovascular structures. They are usually benign, but may involve or infiltrate the bone of the skull base, dura, brain stem and all neurovascular structures in this region, making it difficult to completely remove without causing neurological deficits. The aim of this study is to review a surgical series of petroclival meningioma treated in a referral center for skull base tumors, considering the determining factors to the choice of approach. The casuistry was analyzed with retrospective data collection. Due to difficult access, these injuries usually require different surgical approaches and have different surgical difficulties. Although the fronto-orbital-zygomatic, petrous, including retrolabyrinthine pre-sigmoid, translabyrinthine and total petrosectomy, and retrosigmoid are frequently used for resection of these tumors, it has not been realized to date comparative study to determine which approach has greater degree of surgical resection associated with lower morbidity rate.
Galvani, Aline Faria [UNESP]. "Análise da Frequência de Polimorfismos nos genes IL28B e IL28R1 em pacientes acometidos por Meningioma." Universidade Estadual Paulista (UNESP), 2015. http://hdl.handle.net/11449/134110.
Повний текст джерелаFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Os meningiomas são os tumores mais frequentes do Sistema Nervoso Central e sua classificação é dada quanto ao tipo celular envolvido e grau de malignidade. Os intérferons (IFNs) foram inicialmente associados à resposta antiviral, contudo, estudos posteriores evidenciaram o envolvimento dessas citocinas na regulação do crescimento celular e no efeito imunomodulatório. A Interleucina 28B (IL28B), membro da família dos IFNs do tipo III, parece estar envolvida na resposta imune antiviral e antitumoral. Sendo assim, o objetivo do presente estudo foi avaliar a frequência de variações genéticas em IL28B e IL28R1 em pacientes acometidos por Meningiomas. Sessenta paciente tratados pelo serviço de Neurocirurgia da UNESP de Botucatu/SP foram incluídos neste estudo. A análise do polimorfismo rs12979860 C/T teve significância estatística quando comparou-se a frequência genotípica da população brasileira em relação a presente casuística. Foi descrito a detecção de novas variações genéticas (missense e silent) nos genes IL28B e IL28R1 ao comparar com as respectivas sequencias referencias disponíveis em banco de dados (NCBI). Estes dados sugerem uma importante relação destas variações genéticas em relação a estrutura e função das proteínas envolvidas, entretanto um estudo mais aprofundado das consequências dessas alterações na gênese e/ou progressão dos meningiomas devem ser considerado
Meningiomas are the most common tumors of the central nervous system, despite being benign and grow slowly, can recur in case of incomplete surgical resection. They are classified according to the cells involved and their rate of malignancy. The role of the immune system in preventing the emergence and progression of tumors has been the subject of many studies in the field of tumor immunology. Interferon (IFNs) were originally associated with antiviral response, however, subsequent studies revealed the involvement of these cytokines in the regulation of cell growth and their immunomodulatory effect.Thus, the aim of this study was to analyze the genetic variation frequency of IL28B and IL28R1 in patients with meningioma. Sixty patients treated by UNESP Neurosurgery service of Botucatu/SP were included in this study. Polymorphism rs12979860 C/T analysis showed statistical significance when compared with healthy Brazilian's genotypic frequency. New genetic variation (missense and silent) were detected in IL28B and IL28R1 through reference sequences analysis (NCBI). These data support an important relation of these genetic variations related to protein functions, however other studies of the consequences of these changes in the development and progression of meningiomas should be considered
Galvani, Aline Faria. "Análise da Frequência de Polimorfismos nos genes IL28B e IL28R1 em pacientes acometidos por Meningioma /." Botucatu, 2015. http://hdl.handle.net/11449/134110.
Повний текст джерелаCoorientador: Adriana Camargo Ferrasi
Banca: Sílvia Helena Barem Rabenhorst
Banca: Marcelo Lima Ribeiro
Resumo: Os meningiomas são os tumores mais frequentes do Sistema Nervoso Central e sua classificação é dada quanto ao tipo celular envolvido e grau de malignidade. Os intérferons (IFNs) foram inicialmente associados à resposta antiviral, contudo, estudos posteriores evidenciaram o envolvimento dessas citocinas na regulação do crescimento celular e no efeito imunomodulatório. A Interleucina 28B (IL28B), membro da família dos IFNs do tipo III, parece estar envolvida na resposta imune antiviral e antitumoral. Sendo assim, o objetivo do presente estudo foi avaliar a frequência de variações genéticas em IL28B e IL28R1 em pacientes acometidos por Meningiomas. Sessenta paciente tratados pelo serviço de Neurocirurgia da UNESP de Botucatu/SP foram incluídos neste estudo. A análise do polimorfismo rs12979860 C/T teve significância estatística quando comparou-se a frequência genotípica da população brasileira em relação a presente casuística. Foi descrito a detecção de novas variações genéticas (missense e silent) nos genes IL28B e IL28R1 ao comparar com as respectivas sequencias referencias disponíveis em banco de dados (NCBI). Estes dados sugerem uma importante relação destas variações genéticas em relação a estrutura e função das proteínas envolvidas, entretanto um estudo mais aprofundado das consequências dessas alterações na gênese e/ou progressão dos meningiomas devem ser considerado
Abstract: Meningiomas are the most common tumors of the central nervous system, despite being benign and grow slowly, can recur in case of incomplete surgical resection. They are classified according to the cells involved and their rate of malignancy. The role of the immune system in preventing the emergence and progression of tumors has been the subject of many studies in the field of tumor immunology. Interferon (IFNs) were originally associated with antiviral response, however, subsequent studies revealed the involvement of these cytokines in the regulation of cell growth and their immunomodulatory effect.Thus, the aim of this study was to analyze the genetic variation frequency of IL28B and IL28R1 in patients with meningioma. Sixty patients treated by UNESP Neurosurgery service of Botucatu/SP were included in this study. Polymorphism rs12979860 C/T analysis showed statistical significance when compared with healthy Brazilian's genotypic frequency. New genetic variation (missense and silent) were detected in IL28B and IL28R1 through reference sequences analysis (NCBI). These data support an important relation of these genetic variations related to protein functions, however other studies of the consequences of these changes in the development and progression of meningiomas should be considered
Mestre
Simis, André. "Edema peritumoral em meningiomas benignos: correlação com fatores clínicos, radiológicos, cirúrgicos e com recorrência tumoral." Universidade de São Paulo, 2007. http://www.teses.usp.br/teses/disponiveis/5/5138/tde-12022008-132122/.
Повний текст джерелаINTRODUCTION: Approximately 60% of meningiomas are associated with peritumoral edema.Various causative factors have been discussed in the literature. PURPOSES: Investigate the correlation of peritumoral edema with clinical, radiological and surgical aspects, and recurrence rate of meningiomas. METHODS: Sixty one benign meningiomas submitted to surgical treatment by the Group of Brain Tumors and Metastasis of the Division of Neurosurgery of the Hospital das Clínicas of São Paulo Medical School of São Paulo University. All patients underwent complete surgical ressection (Simpson 1 and 2) and were excluded the atypical and malignant hystopathological grades. The tumors located in the cavernous sinus, tuberculum sellae region, foramen magnum region, ventricular space and petroclival region were excluded. RESULTS: Edema extention had a positive correlation with the higher recurrence rates (p = 0,042) and with the presence of irregular margins (p < 0,011) on bivariate analysis. Meningiomas with greater edema sizes also showed correlation with large meningiomas (p = 0,035) and the ones with smaller edema sizes correlated with the tentorial location (p=0,032). Multivariate analysis showed an association between peritumoral brain edema and the presence of seizures (Odds ratio=3,469), large meningiomas (Odds ratio=15,977), and for each cubic centimeter added to its size, the risk of edema increased 1,082 times (Odds ratio). CONCLUSION: Peritumoral brain edema correlated with recurrence, irregular margins, seizures and larger tumors. The tentorial location demonstrated smaller edema sizes. Peritumoral brain edema may be related to meningioma\'s invading potentiality and may play a role in the recurrence pontential of the tumor. As a consequence, it\'s reasonable to consider edema\'s presence as an additional factor to be taken into account when arranging layout of strategies for meningiomas treatment.
Andersson, Ulrika. "Experimental studies in brain tumours : with special regard to multidrug resistance and the ErbB-family." Doctoral thesis, Umeå : Strålningsvetenskaper, Umeå universitet, 2005. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-521.
Повний текст джерелаDIAZ, JUAN. "Tumeurs cerebrales a expression psychiatrique : a propos d'un cas de meningiome temporal." Université Louis Pasteur (Strasbourg) (1971-2008), 1993. http://www.theses.fr/1993STR1M042.
Повний текст джерелаCoelho, Francisco Manuel Leão de Sá. "Análise do tempo de sobrevida após o diagnóstico de meningioma intracraniano canino e sua relação com os sinais neurológicos, localização tumoral e tratamento instituído." Master's thesis, Universidade de Lisboa, Faculdade de Medicina Veterinária, 2021. http://hdl.handle.net/10400.5/21683.
Повний текст джерелаRESUMO - Para a análise do tempo de sobrevida de cães com meningioma intracraniano canino em função do tratamento aplicado, e avaliação dos sinais neurológicos e localização tumoral como possíveis fatores de prognóstico, foi realizado um estudo retrospetivo com inclusão de 49 cães com diagnóstico presuntivo (n=42) ou definitivo (n=7) de meningioma intracraniano, agrupados consoante o tratamento instituído: farmacológico (n=38) – paliativo (n=32) ou quimioterapia (n=6) – e cirúrgico (n=11) – cirurgia (n=7) ou cirurgia e quimioterapia (n=4). A mediana do tempo de sobrevida (MTS) para o grupo submetido a tratamento paliativo foi de 147 dias (4,9 meses), já quando apenas executada cirurgia esta foi de 129 dias (4,3 meses). A administração de quimioterapia isolada ou adjuvante à cirurgia resultou numa MTS de 360 dias (11,8 meses) e 468 dias (15,6 meses), respetivamente, demonstrando um efeito positivo no tempo de sobrevida dos cães com meningioma intracraniano. Não se verificou diferença entre as curvas de distribuição de tempos de sobrevida de cada grupo de tratamento (p=0,156). Contudo, para p<0,1, os cães com meningioma intracraniano presuntivo inseridos no grupo de tratamento paliativo tinham cerca de 1,926 e 2,832 vezes maior probabilidade de morrer a qualquer instante do que se incluídos em outro grupo de tratamento (p=0,051) ou a tratamento multimodal com cirurgia e quimioterapia (p=0,095). Mais frequentemente o meningioma foi rostrotentorial (61,2%, n=30) (p=0,116), mais associado à apresentação de crises epiletiformes (p<0,001) e exame neurológico sem alterações significativas (p=0,023). A síndrome vestibular (p=0,002), a dor neuropática (p=0,041) e os problemas na marcha (p=0,006) resultam mais provavelmente da presença de um meningioma infratentorial. Cães com meningioma intracraniano sem problemas na marcha e défices propriocetivos sobreviveram significativamente mais tempo (p=0,020), sendo que para p<0,01, a localização infratentorial (p=0,084) e presença de problemas na marcha (p=0,020) estão associadas a uma maior probabilidade de morrer a qualquer instante. A administração de quimioterapia adjuvante à cirurgia para o tratamento de meningioma intracraniano canino parece vantajosa. Adicionalmente, é possível que a associação de quimioterapia ao tratamento paliativo aumente a eficácia do protocolo farmacológico. Localização infratentorial e manifestação de problemas na marcha e/ou défices propriocetivos podem conferir um pior prognóstico em cães com meningioma intracraniano presuntivo.
ABSTRACT - Survival Analysis after Canine Intracranial Meningioma Diagnosis and its Relationship with Neurologic Signs, Tumor Location and Followed Treatment - For survival analysis of dogs with canine intracranial meningioma as a function of applied treatment, and evaluation of neurological signs and tumor localization as possible prognostic factors, a retrospective study was conducted including 49 dogs with presumptive (n=42) or definitive (n=7) diagnosis of intracranial meningioma, grouped according to followed treatment: medical (n=38) - palliative (n=32) or chemotherapy (n=6) – and surgical (n=11) – surgery (n=7) or surgery and chemotherapy (n=4). Median survival time (MST) for palliative treatment group was 147 days (4.9 months), and 129 days (4,3 months) when only surgery was performed. With a positive effect on survival time of dogs with intracranial meningioma, the administration of chemotherapy alone or in combination with surgery resulted in 360 days (11.8 months) and 468 days (15.6 months) MST, respectively. There was no difference between the survival time distribution curves of each treatment group (p=0.156). However, for p<0.1, dogs with presumptive intracranial meningioma included in the palliative treatment group were about 1.926 and 2.832 times more likely to die at any point of time than if included in another treatment group (p=0.051) or multimodal treatment with surgery and chemotherapy group (p=0.095). More often, meningioma was rostrotentorial (61.2%, n=30) (p=0.116), more associated with the seizures (p<0.001) and normal neurological examination (p=0.023). Vestibular syndrome (p=0.002), neuropathic pain (p=0.041) and impaired gait (p=0.006) are more likely to result from the presence of an infratentorial meningioma. Dogs with intracranial meningioma without impaired gait and propriocetive deficits survived significantly more (p=0.020), and for p<0.01, infratentorial location (p=0.084) and impaired gait (p=0.020) were associated with a higher probability of dying at any moment. Surgical intervention followed by chemotherapy administration seems advantageous for the treatment of canine intracranial meningioma. Additionally, it may be possible that chemotherapy in combination with palliative treatment increases medical treatment effectiveness. Infratentorial localization and impaired gait and/or propriocetive deficits may indicate worse prognosis in dogs with presumptive intracranial meningioma.
N/A
Quach, Pauline. "Lifestyle Risk Factors Associated with Adult Primary Brain Tumours: Quality Assessment of Existing Systematic Reviews, Followed by Updated Analyses and De-Novo Syntheses." Thèse, Université d'Ottawa / University of Ottawa, 2013. http://hdl.handle.net/10393/26243.
Повний текст джерелаFOLACCI, JEAN-LUC. "Les metastases des cancers visceraux dans les tumeurs benignes intra-craniennes : a propos d'une metastase d'un cancer thyroidien dans un meningiome intracranien." Nice, 1988. http://www.theses.fr/1988NICE6560.
Повний текст джерелаLyons, Rimmer Jade. "The potential of CRL4-DCAF1 and KSR1 as therapeutic targets in low-grade Merlin-deficient tumours." Thesis, University of Plymouth, 2018. http://hdl.handle.net/10026.1/12833.
Повний текст джерелаSILVA, Geanny Pereira da. "Análise de alterações no número de cópias envolvendo os cromossomos 1p e 22 em meningiomas de baixo grau." Universidade Federal do Pará, 2013. http://repositorio.ufpa.br/jspui/handle/2011/8087.
Повний текст джерелаApproved for entry into archive by Edisangela Bastos (edisangela@ufpa.br) on 2017-04-05T14:46:17Z (GMT) No. of bitstreams: 2 license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Dissertacao_AnaliseAlteracoesNumero.pdf: 1579411 bytes, checksum: 25990e97eda3beed8df2da4e15eaa1ad (MD5)
Made available in DSpace on 2017-04-05T14:46:17Z (GMT). No. of bitstreams: 2 license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Dissertacao_AnaliseAlteracoesNumero.pdf: 1579411 bytes, checksum: 25990e97eda3beed8df2da4e15eaa1ad (MD5) Previous issue date: 2013-12-13
CNPq - Conselho Nacional de Desenvolvimento Científico e Tecnológico
Os meningiomas constituem o segundo tipo de tumor primários cerebral mais comum, originando-se nas meninges que revestem o cérebro e a medula espinhal. Possuem crescimento lento, sendo encontrados com maior freqüência no SNC. Na maioria dos casos são benignos, porém há também casos de meningiomas classificados como malignos. No nível citogenético, os meningiomas são os tumores mais bem estudados em humanos, e os resultados demonstraram que as alterações mais frequentes nesse tipo de tumor tem sido a perda de uma cópia do cromossomo 22 e a deleção do braço curto do cromossomo 1. Essas alterações têm sido associadas ao processo de gênese tumoral, por serem características de tumores de baixo grau, principalmente deleções envolvendo o cromossomo 22. Dessa forma, o objetivo do presente trabalho foi analisar a recorrência de alterações no número de cópias (CNAs) envolvendo os cromossomos 1p e 22 em meningiomas de grau I e II, além de averiguar a existência de outros rearranjos recorrentes, por meio da análise genômica comparativa de alta resolução (array-CGH). As amostras analisadas foram provenientes de oito pacientes. Todas as amostras apresentaram ganhos e perdas de diversos segmentos cromossômicos. Com exceção de um caso, todos os outros apresentaram em maior ou menor grau mais deleções do que amplificações. A perda de segmentos localizados em 1p foi observada em todas as amostras analisadas. Algumas CNAs apresentaram recorrência em até seis dos oito casos. O cromossomo 22 apresentou CNAs em todas as amostras, mas a monossomia total só foi observada em duas das oito amostras. A análise global de CNAs em todas as amostras demonstrou que, apesar de alterações em 1p e 22 serem as modificações mais observadas, como o esperado, outras regiões genômicas também se apresentaram modificadas em várias amostras, apontando para um possível envolvimento dessas modificações com o processo de tumorigênese e progressão tumoral. Algumas delas, como alterações nos pares 9, 12 e 17, já foram observadas em outros trabalhos e foram correlacionadas com meningiomas atípicos e anaplásicos. Dessa forma, os dados obtidos apontam para a existência de um número maior de alterações genômicas em meningiomas de baixo grau, refutando, em parte, a afirmação de que esses tumores são caracterizados por um pequeno número de alterações quando comparados com tumores de malignidade maior. No entanto, o fato desses tumores apresentarem as alterações que são clássicas dos meningiomas, mesmo os benignos, como as deleções em 1p e em 22q, pode ser um indício de que estas alterações devem estar ligadas com os eventos iniciais destes meningiomas, como já foi sugerido diversas vezes por outros autores. Concluindo, essas alterações permanecem como marcadores importantes em meningiomas, e as relações dessas e outras CNAs com a resposta a diferentes tratamentos e ocorrência de recidivas devem ser o próximo passo após a caracterização citogenômica baseada em array-CGH.
Meningiomas are the second most common type of primary brain tumor, originating in the meninges covering the brain and spinal cord. They show slow growth, and are found more often in the CNS, being benign in most case, although there are also cases of meningiomas classified as malignant. At the cytogenetic level, meningiomas are the most well studied tumors in humans: studies in CNS tumors have shown that most cases had chromosomal abnormalities, and the most common alterations in theis type of tumor are the loss of one copy of chromosome 22 and deletion of the short arm of chromosome 1. These alterations have been associated with the tumorigenesis process, because they are found mostly in low-grade tumors, particularly deletions involving chromosome 22. Thus, the aim of this study was to analyze the occurrence of copy number alterations (CNAs) involving chromosomes 1p and 22 meningiomas grade I and II, and in addition to verifying the existence of other recurrent rearrangements through the application of high resolution comparative genomic hybridization (array - CGH ). Tumor samples were collected from eight patients. All samples showed gains and losses of various chromosomal segments. Except for one case, all others showed, in different degrees though, more deletions than amplifications. Loss of 1p segments was observed in all samples. Some CNAs were recurrent, being found up to six out of the eight cases. Pair 22 showed CNV in all samples, but the total monosomy was observed in only two of the eight samples. The global analysis of CNAs in all samples showed that, although changes 1p and 22 were the most frequent observed alterations, as expected, other genomic regions had also alterations in various samples, indicating a possible involvement of these modifications in the process of tumorigenesis and tumor progression. For instance, alterations in pairs 9, 12 and 17, have been observed in other studies and were correlated with atypical and anaplastic meningiomas. Our data indicate the existence of a larger number of genomic alterations in low-grade meningiomas, disagreeing partly with the assumption that these tumors are characterized by a small number of changes, usually involving pair 22 and, less frquently, loss of 1p. However, the fact that these tumors present alterations that are classically found in meningiomas, even benign, such as deletions in 1p and 22q, may be an indication that these changes must be linked with the early events of origin in meningiomas, as already suggested several times by other authors . In conclusion, these alterations remain important markers in meningiomas, and the relationships of these and other CNAs with the response to different treatments and recurrences should be the next step after cytogenomic characterization based on array-CGH has been completed.
LOPES, Cleiton Mendes. "Análises dos genes TP53, PTEN, IDH1 e IDH2 em tumores não gliais do sistema nervoso humano." Universidade Federal do Pará, 2016. http://repositorio.ufpa.br/jspui/handle/2011/8059.
Повний текст джерелаApproved for entry into archive by Edisangela Bastos (edisangela@ufpa.br) on 2017-03-30T12:15:36Z (GMT) No. of bitstreams: 2 license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Dissertacao_AnaliseGenesTP53.pdf: 906769 bytes, checksum: 868736765e91f437e42d5aca6b356441 (MD5)
Made available in DSpace on 2017-03-30T12:15:36Z (GMT). No. of bitstreams: 2 license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Dissertacao_AnaliseGenesTP53.pdf: 906769 bytes, checksum: 868736765e91f437e42d5aca6b356441 (MD5) Previous issue date: 2016-06-17
CAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
CNPq - Conselho Nacional de Desenvolvimento Científico e Tecnológico
Apesar da considerável incidência, estudos de alterações genéticas nos genes TP53, PTEN, IDH1 e IDH2, em tumores não gliais, são raros e, em alguns casos, inexistentes. Os tumores não gliais são classificados geralmente como benignos e raramente evoluem à malignidade, apresentando diferentes classificações, incidências e localizações. Os genes supressores tumorais e de resposta a danos ao DNA, TP53 e PTEN, estão entre os genes mais frequentemente mutados em tumores humanos. Os genes IDH1 e IDH2 estão envolvidos no metabolismo celular e, também, foram encontrados frequentemente mutados em gliomas, melanomas e leucemias, sendo atualmente considerados como bons marcadores em gliomas. Foram realizadas análises de alterações genéticas nos genes citados, a fim de verificar se estão associados à etiologia e/ou progressão de tumores não gliais do Sistema Nervoso Humano (SNH). Foram utilizadas as técnicas de PCR-SSCP para amplificação da região de interesse e triagem mutacional das amostras para posterior sequenciamento. Foram analisadas 37 amostras de tumores não gliais (14 schwannomas, 3 Meningiomas, 4 Meduloblastomas, 2 Neurocitomas e 14 Metástases do Sistema Nervoso Central (SNC). Somente o gene IDH1 apresentou polimorfismos na SSCP em 12 (32,4%) amostras, sendo, então, submetidas ao sequenciamento. No entanto, as reações de sequenciamento foram satisfatórias em apenas em 5 amostras, entre as polimórficas, (1 metástase, 1 meningioma e 3 schwanomas,). Análises dessas 5 amostras identificaram diferentes mutações, uma delas, presente em todas, uma transversão T→A no éxon 4 do códon 106 do gene IDH1, resultando na substituição do aminoácido treonina por serina. Foram, também, identificadas outras mutações em regiões não codificantes (íntron 4) do gene IDH1 em duas dessas amostras. As mutações encontradas em nosso estudo ainda não haviam sido relatadas na literatura. Nossos resultados indicam a participação do gene IDH1 na patogênese desses tumores.
Despite the considerable incidence, studies of genetic changes in gene TP53, PTEN, IDH2 and IDH1, in not glial tumors are rare and, in some cases, nonexistent. Glial tumors are usually not classified as benign and rarely evolve to malignancy, with different classifications, effects and locations. The tumor suppressor genes and response to DNA damage, TP53 and PTEN are among the most commonly mutated gene in human tumors. The genes IDH1 and IDH2 are involved in cell metabolism and also were frequently found mutated in gliomas, melanomas and leukemias, currently being considered as good markers for gliomas. Genetic analyzes were performed in those genes, in order to verify that are associated with the etiology and/or progression of non-glial tumors of Human Nervous System (HNS). SSCPPCR techniques for the amplification of the region of interest and mutational screening of samples for subsequent sequencing were used. We analyzed 37 samples of non-glial tumors (14 schwannomas, meningiomas 3, 4 Medulloblastomas, 2 neurocytomas and 14 metastases of Central Nervous System (CNS). Only the gene IDH1 polymorphisms presented on the SSCP 12 (32.4%) samples, and then subjected to sequencing. However, sequencing reactions were satisfactory in only 5 samples, of the polymorphic, (1 metastasis, meningioma 1 and 3 schwannomas). Analysis of these samples have identified 5 different mutations, one present in all, one transversion T → A in codon 106 of exon 4 of the IDH1 gene resulting in amino acid substitution of threonine by serine. Were also identified other mutations in noncoding regions (intron 4) of gene IDH1 in two of these samples. The mutations found in our study had not yet been reported in the literature. Our results indicate the participation the gene IDH1 in the pathogenesis of these tumors.
Mainio, A. (Arja). "Depressive and anxious symptomatology in relation to a primary brain tumor:prospective study of neurosurgical patients in Northern Finland." Doctoral thesis, University of Oulu, 2005. http://urn.fi/urn:isbn:9514277163.
Повний текст джерелаChakrama, Fatima Zahra. "La protéine Gec1/Gabarapl1 : rôle au cours de l'autophagie et expression dans les cellules cancéreuses." Thesis, Besançon, 2011. http://www.theses.fr/2011BESA3007/document.
Повний текст джерелаThe Gec1 / Gabarapl1 gene was identified in our laboratory as an early estrogen regulated gene. Gabarapl1 belongs to the Gabarap family, also including Gabarap, Gabarapl2 and Gabarapl3 genes, that encode proteins which present high sequence homology with each other. A functional study of the Gabarapl 1 protein showed that this protein is involved in the transport of receptors such as the Gabaₐ and κ-opioid receptors via its interaction with tubulin and NSF. It has been reported that the Atg8 family proteins are involved in autophagy, a mechanism of degradation and cell survival that is charactenzed by the formation of double membranes called autophagosomes. The aims of my research were, firstly, to characterize the role of the Gabarapl1 protein during autophagy and, secondly, to study its expression in cancer cell lines and cancerous tissues and its regulation in response to anti-cancer drugs. First, we showed that Gabarapl1 is cleaved in the cells by the protease Atg4B at its 116 glycine residue prior to its conjugation to phospholipids. This modified form, lipidated, is located on the surface of autophagosomes and lysosomes. We then showed that Gabarapl1 expression is reduced in many cancer cell lines, and that its expression is also altered in meningiomas. Finally, we showed that Gabarapl1 expression is regulated by proteasom€: inhibitors. Thus, our results demonstrated for the first time that the Gabarapl1 protein is associatec with autophagie vesicles and allow us to propose hypothesis for future work
Graillon, Thomas. "Etudes des voies somatostatinergiques et Pi3Kinase-Akt-mTOR dans les tumeurs intra-crâniennes (Adénomes hypophysaires, Méningiomes, Chordomes)." Thesis, Aix-Marseille, 2014. http://www.theses.fr/2014AIXM5053.
Повний текст джерела1.Somatotroph adenomas : Development of an in vitro and in vivo model to study SST2 receptor and somatostatin pathway.To precise SST2 role in tumorigenesis, we developed an in vitro and in vivo model, using a polyclonal cell line with high and stable SST2 expression level. This model will provide to test new somatostatin agonists as pasireotide and further studies on intracellular pathway in ''somatotroph'' context.2. Meningiomas : Development of a model of meningioma primary culture in vitro with study of octreotide, pasireoide and everolimus effects on cell proliferation and intracellular pathways. Given the strong SST2 expression, we demonstrated an in vitro antiproliferative effect of octreotide on meningioma cells via an inhibition of Pi3kinase-Akt-mTOR pathway.In vitro, we observed that octreotide significantly improved everolimus induced cell proliferation inhibition. An additive effect of the 2 drugs was observed in each tested tumor. These results supported the development of a clinical trial. Pasireotide provided a better effect than octreotide, alone or in combination with everolimus on cell proliferation and intracellular pathways.3. Chordomas : Development of an in vitro model of chordoma cell primary culture with preliminary studies.We developed a model of in vitro chordoma cell culture. This model is reliable and stable, providing study of different drugs. SST2 receptor expression was lower than in meningiomas but SST2 expression remained significant in the majority of the tumors. First results with octreotide, pasireotide and everolimus are relevant, with a decrease in cell proliferation leading to further studies
Ando, H., A. Natsume, T. Senga, R. Watanabe, I. Ito, M. Ohno, K. Iwami, et al. "Peptide-based inhibition of the HOXA9/PBX interaction retards the growth of human meningioma." 2013. http://hdl.handle.net/10454/10104.
Повний текст джерелаBackground Meningiomas are the most common type of intracranial tumor, accounting for between 24 and 30 % of primary intracranial tumors. Thus far, no biomarkers exist to reliably predict the clinical outcome of meningiomas. A previous genome-wide methylation analysis revealed that HOXA9 is one of the most functionally relevant biomarkers. In this study, we have examined whether HOXA9 is a potential therapeutic target in meningiomas, using HXR9, a peptide inhibitor of the interaction between HOXA9 and its cofactor PBX. Methods We determined the expression level of HOXA9 in human meningiomas, meningioma cell lines, and normal brain tissue. Meningioma in culture and in subcutaneous tumors was treated with HXR9. We also examined the disruption of HOXA9/PBX dimers. Results We first confirmed that HOXA9 is highly expressed in meningiomas, but not in normal brain tissue. The HXR9 peptide blocks the binding of HOXA9 to PBX, leading to an alteration of DNA binding, and subsequent regulation of their target genes. HXR9 markedly inhibited the growth of meningioma cells and subcutaneous meningeal tumors. Conclusion There is no effective chemotherapy for meningiomas at present, and targeting the HOXA9/PBX interaction may represent a novel treatment option for this disease.
Magalhães, Tomás Rodrigues. "Efeito da radioterapia no tratamento de tumores intracranianos no cão: meningiomas e gliomas." Master's thesis, 2016. http://hdl.handle.net/10348/7713.
Повний текст джерелаA radioterapia tem sido considerada a terapia de eleição para vários tumores cerebrais no cão, nomeadamente o glioma e o meningioma intracraniano. Após ter sido realizada uma revisão acerca da técnica e dos dois tipos de tumor, em particular, procedeu-se à realização de um estudo de caráter retrospetivo, com dados relativos a doentes tratados no hospital VRCC - Veterinary Referrals, no Reino Unido. Os objetivos definidos foram avaliar a eficácia desta abordagem terapêutica e procurar estabelecer associações entre várias características epidemiológicas, clínicas, diagnósticas e terapêuticas com o tipo tumoral e os tempos de sobrevivência apresentados. Assim, foram incluídos 32 cães com diagnóstico de glioma ou meningioma intracraniano, tratados com radioterapia, cujos relatórios clínicos foram analisados. Procedeu-se, ainda, ao cálculo de dois tempos de sobrevivência: o total (TST) e o pós-tratamento (TSPT), que se assumiram desde o diagnóstico ou do fim da radioterapia, respetivamente, até à morte ou final do período de estudo. Apenas 30 doentes foram considerados para os cálculos de sobrevida. O sexo e o realce pós-contraste exibiram associações estatisticamente significativas (P<0.05) com o diagnóstico tumoral. Estes resultados traduziram-se numa predisposição sexual dos machos para o tipo glial e das fêmeas para o tipo meningeal e numa maior especificidade do realce pós-contraste, observado na ressonância magnética, para o meningioma. Verificou-se, ainda, que, apenas, a raça e o sexo se assumiram como fatores de prognóstico, tendo estado associados significativamente (P<0.05) com os tempos de sobrevivência. Ser da raça boxer ou labrador retriever, bem como ser fêmea constituem, assim, um benefício na sobrevida destes doentes. Os valores medianos obtidos foram de 372 dias para o TSPT e de 446.5 dias para o TST, em termos globais. As taxas de sobrevida ao final de 1 e 2 anos foram, respetivamente, de 50% e 23.3%. A radioterapia é, assim, uma metodologia de tratamento eficaz nestes quadros neoplásicos, apresentando resultados superiores a outras abordagens terapêuticas.
Radiation therapy has been considered the treatment of choice for many brain tumors in dogs, like glioma and intracranial meningioma. After a review about the technique and these two types of tumor, in particular, a retrospective study was carried out, with the informations of patients treated in the hospital VRCC - Veterinary Referrals, in United Kingdom. The goals were set to evaluate the efficacy of this therapeutic approach and to search associations between different epidemiological, clinical, diagnostic and therapeutic features with the tumor type and the survival times. This study included 32 dogs diagnosed with glioma and intracranial meningioma which undergone radiation therapy. The clinical reports were analyzed. Two survival times were calculated: overall (OST) and post-treatment (PTST), from the diagnosis or the end of the radiation, respectively, until death or end of the study period. Only 30 patientes were considered for these survival calculations. Sex and contrast enhancement exhibited statistically significant associations (P<0.05) with tumor diagnosis. These results showed a sexual predisposition of males for glial type and females for meningeal type and a greater specificity of contrast enhancement, observed on MRI, for meningioma. It was found that just the breed and the sex are prognostic factors, as they were significantly associated (P<0.05) with survival times. Boxer and labrador retriever breeds and the female sex were considered as a survival benefit in these patients. Median values were 372 days for TSPT and 446.5 days for the TST. The 1- and 2-year survival rates were, respectively, 50% and 23.3%. Thus, radiation therapy is an effective treatment option for these neoplastic cases, with better results than other therapeutic approaches.
Chuan-Fu and 黃全福. "Diffusion Magnetic Resonance Imaging in the Evaluation of the Response of Meningioma and Metastatic Brain Tumor Treated by Gamma Knife Radiosurgery." Thesis, 2009. http://ndltd.ncl.edu.tw/handle/63379861568281181930.
Повний текст джерела中山醫學大學
醫學研究所
97
Background: Patients usually receive serial magnetic resonance imaging (MRI) examinations to assess stereotactic radiosurgery (SRS) effects by volume change. But loss of tumor cell after radiosurgical treatment results in a relative increase in extracellular space and may lead to alteration of apparent diffusion constant (ADC). Our hypothesis is to investigate if the ADC can be used, rather than with methods depending on changes in tumor size, to predict treatment success after treatment of meningioma and brain metastases with SRS. Methods: We conducted a prospective trial involving 6 patients with intracranial meningiomas and 21 patients with 32 solid or solid-dominated lesions treated by SRS with 201-source cobalt in our Gamma Knife center. Patients received complete diffusion MRI before treatment and at multiple intervals following SRS. We followed up MRI findings and clinical outcomes at 3 months, and thereafter in 3-month intervals. We detected the long-term results of diffusion MRI in 7 patients treated for at least 5 years. We calculated apparent diffusion coefficients (ADC) from echoplanar diffusion weighted imaging, and compared mean ADC values. Mean ADC values at the various time intervals were compared with each other to see whether or not the ADC might be used as an early indicator of treatment success or failure. Results: The ADC for meningioma was 0.55-0.64 x 10-3 mm2/s (mean ± SD). We observed 2 ADC phase changes after SRS: a significant (p < 0.05) reduction phase beginning at 4 hours and lasting 4 days after SRS followed by an elevation phase to pseudonormalized values. ADC significantly increased 30 days after SRS, reaching a plateau in 3 months. MRI follow-up at 3-month intervals showed stable tumor size in all patients, with 3 patients revealing evidence of tumor necrosis. The ADC value for the long-term group was 1.26 x 10-3 mm2/s. (p < 0.05); however, MRI follow-up showed tumor shrinkage in 3 patients. The mean pre-treatment value of the ADC in the metastatic tumors was 1.05 ± 0.12 x10-3 mm2/s. This value for the tumors rose significantly (P=0.009) seven days after SRS and continued to rise with time. Magnetic resonance imaging (MRI) showed that 91% of these tumors had been controlled by the SRS. ADC values in cystic/necrotic tumor tissue (2.13 ± 0.18 x 10-3 mm2/s) were significantly (P<0.001) higher than in non-central necrotic tumor tissue (1.61 ± 0.14 x 10-3 mm2/s). Conclusion: Gamma knife treatment is efficacious for meningioma and metastatic brain tumors. Serial changes in ADC values might eventually be useful to evaluate treatment success and in some patients even detected at early time points, and to distinguish radiation-induced central necrosis from tumor re-growth in cases where other imagery is not definitive.